India's Natco Pharma rises after US FDA closes inspection without urging action

** Shares of Natco Pharma NATCOPHARM rise 3% to 883.20 rupees

** U.S. Food and Drug Administration (FDA) completed inspection at its Hyderabad plant, classifying the facility as Voluntary Action Indicated (VAI)

** VAI indicates the agency is not prepared to take or recommend any administrative or regulatory action, per the FDA website

** Co had said inspection was "procedural" and that it was confident it could address it comprehensively

** Stock, on avg, rated "hold" with median PT 983.50 rupees - data compiled by LSEG

** Stock down 36% YTD